pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Phase 3 · small molecule · Sarcoidosis
This program combines prednisone (a corticosteroid) and hydroxychloroquine for the treatment of pulmonary sarcoidosis, sponsored by Pari Pharma GmbH. The QUIDOSE randomized controlled trial is currently in Phase 3 development, evaluating the efficacy of hydroxychloroquine combined with low-dose corticosteroid therapy.
Internal code APHP191105
This program combines prednisone (a corticosteroid) and hydroxychloroquine for the treatment of pulmonary sarcoidosis, sponsored by Pari Pharma GmbH. The QUIDOSE randomized controlled trial is currently in Phase 3 development, evaluating the efficacy of hydroxychloroquine combined with low-dose corticosteroid therapy. Prednisone is an established oral corticosteroid with extensive regulatory approval history across multiple jurisdictions including Australia and the United States, where it has been marketed under various brand names including PANAFCORT. The program represents a combination therapy approach to sarcoidosis management, leveraging existing approved agents. Current development status is active, with the Phase 3 QUIDOSE trial ongoing. Regulatory pathways and approval timelines have not yet been disclosed. The strategy appears focused on optimizing existing therapeutic agents through combination dosing strategies rather than developing novel molecular entities.
Sarcoidosis is a multisystem inflammatory disorder with significant pulmonary manifestations affecting quality of life and organ function. Current standard-of-care corticosteroid monotherapy carries substantial long-term toxicity concerns, creating an unmet medical need for improved therapeutic strategies that reduce corticosteroid burden while maintaining efficacy. This combination approach addresses a clinically relevant gap by investigating whether hydroxychloroquine can enable lower corticosteroid doses, potentially reducing adverse effects associated with prolonged corticosteroid exposure such as osteoporosis, metabolic complications, and immunosuppression. The pulmonary sarcoidosis patient population represents a significant commercial opportunity given disease prevalence and chronic treatment requirements. Successful demonstration of efficacy with reduced corticosteroid exposure could establish a new standard-of-care regimen, offering competitive advantages over corticosteroid monotherapy. The program's market relevance is substantial given the chronic nature of sarcoidosis and the substantial patient burden from current therapeutic limitations. Commercial significance is enhanced by the use of established, off-patent agents, potentially enabling rapid market penetration and favorable reimbursement profiles compared to novel therapeutics.
Drug Class: Combination immunosuppressive/anti-inflammatory therapy
Components:
Modality: Small molecule
Route of Administration: Oral
Target: Not yet disclosed
Related Therapies: Corticosteroid monotherapy (standard of care); methotrexate-based regimens; sirolimus (Phase 2, same sponsor)
First Approval: Prednisone approved in United States and Australia with extensive historical approval dating to 1991 in Australia and multiple decades in the United States under numerous manufacturers and brand names
Patent Status: Not yet disclosed; constituent agents are off-patent
Also known as: Besnier-Boeck-Schaumann disease, Boeck sarcoid, Boeck's sarcoid, Boeck's sarcoidosis, Darier-Roussy sarcoid, besnier-Boeck-Schaumann syndrome
Prevalence: Point prevalence: 1-5 / 10 000 (Worldwide) — source: Orphanet, validated.
Sarcoidosis is a multisystemic disorder of unknown cause characterized by the formation of immune granulomas in involved organs.
ClinicalTrials.gov lists 189 registered studies for Sarcoidosis, (AACT aggregate).
Phase breakdown: NA (137), PHASE2 (17), PHASE4 (14), PHASE2/PHASE3 (8), PHASE3 (7), PHASE1/PHASE2 (3), EARLY_PHASE1 (2), PHASE1 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0019338), Orphanet — sarcoidosis, NCT00000596, NCT00001278, NCT00005276, NCT00005531, NCT00005542, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
QUIDOSE Phase 3 trial ongoing
Randomized controlled trial testing efficacy of hydroxychloroquine combined with low-dose corticosteroid therapy in pulmonary sarcoidosis; trial identifier 2024-516101-23-00.
The sarcoidosis treatment landscape includes several competing approaches. Methotrexate-based combination regimens (Disc Medicine) represent an approved alternative immunosuppressive strategy for steroid-sparing therapy. Sirolimus (Pari Pharma GmbH, Phase 2) represents the same sponsor's parallel investigation of an alternative mechanism for sarcoidosis, suggesting portfolio diversification. Inhaled treprostinil (United Therapeutics Europe Ltd, Phase 2) targets pulmonary vascular complications in sarcoidosis through a distinct mechanism. The QUIDOSE program's competitive positioning relies on the established safety and efficacy profiles of its constituent agents, potentially enabling faster clinical acceptance compared to novel therapeutics, while targeting the clinically important goal of corticosteroid dose reduction. The combination approach differentiates from monotherapy strategies and may offer advantages over methotrexate-based regimens through improved tolerability profiles, though direct comparative data are not yet available.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| METHOTREXATE, METHOTREXATE, PREDNISONE, METHOTREXATE | Disc Medicine | small_molecule | approved |
| [68Ga]Ga-PentixaFor | Disc Medicine | small_molecule | phase_2 |
| SIROLIMUS | Pari Pharma GmbH | small_molecule | phase_2 |
| Inhaled Treprostinil | United Therapeutics Europe Ltd | small_molecule | phase_2 |
| PREDNISONE | — | Glucocorticoid receptor agonist | Approved |
| PREDNISOLONE | — | Glucocorticoid receptor agonist | Approved |
| DEXAMETHASONE SODIUM PHOSPHATE | — | Glucocorticoid receptor agonist | Approved |
| DEXAMETHASONE | — | Glucocorticoid receptor agonist | Approved |
| THALIDOMIDE | — | CRL4(CRBN) E3 ubiquitin ligase inhibitor | Phase 3 |
| MYCOPHENOLIC ACID | — | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 3 |
| METHOTREXATE | — | Dihydrofolate reductase inhibitor | Phase 3 |
| INFLIXIMAB | — | TNF-alpha inhibitor | Phase 3 |
| HYDROXYCHLOROQUINE | — | Toll-like receptor 7 antagonist | Phase 3 |
| USTEKINUMAB | — | Interleukin-23 inhibitor | Phase 2 |
| SARILUMAB | — | Interleukin-6 receptor alpha subunit antagonist | Phase 2 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States: Prednisone approved; marketed by numerous manufacturers under multiple application numbers (NDA009766, NDA009986, NDA010962, NDA017109, NDA202020 and extensive ANDA approvals). Hydroxychloroquine regulatory status not specified in available data.
Australia: Prednisone approved under brand name PANAFCORT; PBS codes 13944X, 14043D, 1934T, 1935W, 1936X; marketed by Aspen Pharmacare Australia Pty Limited and iNova Pharmaceuticals (Australia) Pty Limited with first listings dating 1991-08-01 and 2004-08-01, with recent listing 2024-03-01.
China: Prednisone in clinical trials; NCT identifiers NCT02532790, NCT03321890, NCT05666336, NCT06717347 indicate ongoing investigational activity.
QUIDOSE Program Regulatory Status: Not yet disclosed. Phase 3 development status active; approval timelines and regulatory pathways for the combination formulation not disclosed.
EMA, PMDA, NMPA Status: Not yet disclosed.
The QUIDOSE program combines prednisone and hydroxychloroquine for treatment of pulmonary sarcoidosis, a chronic inflammatory lung disease.
No; the combination is currently in Phase 3 clinical development. Individual components (prednisone and hydroxychloroquine) are approved medications, but the specific combination regimen is investigational.
Prednisone is a corticosteroid that broadly suppresses inflammation and immune responses. Hydroxychloroquine is an antimalarial agent with immunomodulatory properties believed to reduce inflammatory cytokine production. The combination aims to achieve therapeutic efficacy with lower corticosteroid doses.
Pari Pharma GmbH is the sponsor of the QUIDOSE program.
QUIDOSE is a randomized controlled trial (identifier 2024-516101-23-00) testing the efficacy of hydroxychloroquine combined with low-dose corticosteroid therapy in pulmonary sarcoidosis patients.
The program is in Phase 3 development with active trial enrollment and conduct.
Both prednisone and hydroxychloroquine are administered orally.
Yes; prednisone is approved in the United States, Australia, and other jurisdictions under multiple brand names and manufacturers, with extensive historical approval dating decades.
In Australia, prednisone is marketed under the brand name PANAFCORT by Aspen Pharmacare Australia Pty Limited and iNova Pharmaceuticals (Australia) Pty Limited.
Competing approaches include methotrexate-based combination regimens (approved), sirolimus (Phase 2, same sponsor), inhaled treprostinil (Phase 2), and corticosteroid monotherapy (current standard of care).
Current corticosteroid monotherapy for sarcoidosis carries significant long-term toxicity risks. This program addresses the need for therapies that maintain efficacy while reducing corticosteroid exposure and associated adverse effects.
The expected Phase 3 completion date has not yet been disclosed.
Patients with pulmonary sarcoidosis, a chronic inflammatory lung disease affecting multiple organ systems.
Yes; Pari Pharma is also sponsoring a Phase 2 program investigating sirolimus for sarcoidosis, representing portfolio diversification.
The precise mechanism is not fully characterized but is believed to involve reduced inflammatory cytokine production and altered antigen presentation.
No partner is listed for this program; Pari Pharma GmbH is the sole sponsor.
APHP191105 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Pari Pharma's approach leverages existing approved agents to address an unmet medical need in pulmonary sarcoidosis, potentially enabling faster development timelines and regulatory pathways compared to novel therapeutics. The combination strategy targets a clinically meaningful endpoint—corticosteroid dose reduction—that addresses real patient burden from long-term corticosteroid toxicity.
Competitive Implications: Success of QUIDOSE would establish a new standard-of-care regimen potentially superior to corticosteroid monotherapy and competitive with methotrexate-based approaches. The off-patent status of constituent agents provides favorable cost-of-goods and reimbursement positioning. Pari Pharma's parallel Phase 2 sirolimus program suggests portfolio hedging against QUIDOSE outcomes.
Future Catalysts: Phase 3 QUIDOSE trial completion and topline efficacy/safety data represent the critical near-term catalyst. Regulatory submissions and approval decisions will determine market access timelines. Comparative effectiveness data versus methotrexate-based regimens would strengthen competitive positioning.
Expected Milestones: Phase 3 trial completion date not yet disclosed; regulatory filing timelines not disclosed; approval timelines not disclosed. Interim efficacy or safety data releases may occur during ongoing trial conduct.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.